Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Business & education services

Frontier IP portfolio company Vaccine Group installs advisory board of high-ranking veterinary experts

Intellectual property commercialisation specialist Frontier IP Group PLC (AIM:FIPP)’s portfolio company The Vaccine Group (TVG) has formed an advisory board comprising high-ranking veterinary experts to support the scale-up of its innovative herpesvirus-based vaccine platform.

Forming the advisory board marks a crucial step for TVG as it progresses in developing a robust vaccine pipeline for use in livestock, pets and wildlife to tackle a range of viral and bacterial pathogens that cause severe economic harm and can also pose a threat to human health.

The advisory board consists of three high-ranking veterinary experts with strong business experience and connections to major companies and other organisations in the animal health sector.

They are:

  • Christophe Barnier-Quer from Merck Life Science
  • Johan Dreesen, an expert in animal health consultancy and doctor in veterinary medicine, and
  • Vaughn Kubiak, a veteran in global animal health

Their collective expertise spans various facets of veterinary health and business, promising to bring invaluable insights and guidance to TVG.

Neil Crabb, chief executive of Frontier IP, stated: "I am delighted TVG has been able to form an advisory group of such good quality.

“It is a testament to the potential of the company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale-up and full commercialisation."

Jeremy Salt, chief executive of The Vaccine Group, added: "As we approach the end of another successful year for TVG, it is especially positive that we can look forward to gaining the support of three board advisors from January.

“Each of them brings great expertise in their own areas. This will be really helpful for TVG as we grow into a strong player in the global animal health innovation sector."

TVG currently has 12 vaccines under development, addressing diseases like African swine fever, porcine reproductive and respiratory syndrome, and Lassa fever.

All vaccines are based on the company's tunable herpesvirus-based platforms.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK